Upper Respiratory was Perrigo’s largest product and service line in fiscal 2025, bringing in $817.70M of $4.25B (19%).
| Product and Service | FY 2014 | FY 2015 | FY 2015 | FY 2016 | FY 2017 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Branded Otc | — | — | — | — | ||||||||
| Rx | — | — | — | — | ||||||||
| Generic Prescription Drugs | — | — | — | — | ||||||||
| Upper Respiratory | $836.00M | $860.50M | $782.40M | $817.70M | ||||||||
| Skin Care | $572.20M | $613.00M | $630.10M | $622.60M | ||||||||
| Pain & Sleep-Aids | $613.00M | $620.10M | $567.70M | $567.90M | ||||||||
| Healthy Lifestyle | $497.60M | $537.10M | $532.60M | $547.90M | ||||||||
| Skincare & Personal Hygiene | — | — | — | — | ||||||||
| Digestive Health | $534.30M | $548.50M | $533.90M | $482.40M | ||||||||
| Nutrition | $524.30M | $563.20M | $449.50M | $408.50M | ||||||||
| Cough/Cold/Allergy/Sinus | — | — | — | — | ||||||||
| Cough/Cold | — | — | — | — | ||||||||
| Infant Nutritionals | — | — | — | — | ||||||||
| Oral Care | $410.20M | $411.90M | $374.80M | $354.40M | ||||||||
| Analgesics | — | — | — | — | ||||||||
| Gastrointestinal | — | — | — | — | ||||||||
| Other Chci | — | — | — | — | ||||||||
| Other Chca | — | — | — | — | ||||||||
| Smoking Cessation | — | — | — | — | ||||||||
| Vitamins, Minerals, & Supplements | — | — | — | — | ||||||||
| Vitamins, Minerals, & Supplements ("Vms") | $212.20M | $204.00M | $188.00M | $168.40M | ||||||||
| Women's Health | $143.50M | $168.30M | $213.90M | $215.90M | ||||||||
| Vitamins, Minerals & Dietary Supplements | — | — | — | — | ||||||||
| Vitamins, Minerals, & Dietary Supplements | — | — | — | — | ||||||||
| Animal Health | — | — | — | — | ||||||||
| Other Csci | $102.20M | $125.40M | $97.30M | $62.40M | ||||||||
| Active Pharmaceutical Ingredients | — | — | — | — | ||||||||
| Other Csca | $6.10M | $3.60M | $3.10M | $4.80M | ||||||||
| Total | $4.45B | $4.66B | $4.37B | $4.25B |
Perrigo brought in $4.25B from its 11 product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 2.8% from $4.37B in fiscal 2024. Upper Respiratory was the largest at $817.70M (19.2%), ahead of Skin Care at $622.60M (14.6%) and Pain & Sleep-Aids at $567.90M (13.4%). The other eight lines brought in $2.24B combined.
Compared with fiscal 2024, Upper Respiratory grew fastest, up 4.5% to $817.70M, while Vitamins, Minerals, & Supplements ("Vms") fell the most, down 10.4% to $168.40M. From fiscal 2022 to 2025, combined revenue from these lines fell from $4.45B to $4.25B, a compound annual decline of 1.5%. Upper Respiratory's share held steady at about 19.2%.
Csca was Perrigo’s largest segment in fiscal 2025, bringing in $2.59B of $4.25B (61%).
| Segment | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Csca | $2.93B | $2.96B | $2.69B | $2.59B | |||||||||||
| Chc | — | — | — | — | |||||||||||
| Consumer Healthcare | — | — | — | — | |||||||||||
| Chca | — | — | — | — | |||||||||||
| Csci | $1.53B | $1.69B | $1.68B | $1.67B | |||||||||||
| Chci | — | — | — | — | |||||||||||
| Rx | — | — | — | — | |||||||||||
| Rx Pharmaceuticals | — | — | — | — | |||||||||||
| Nutritionals | — | — | — | — | |||||||||||
| Active Pharmaceutical Ingredients | — | — | — | — | |||||||||||
| Other(1) | — | — | — | — | |||||||||||
| All Other Segments | — | — | — | — | |||||||||||
| Pharaceutical & Medical Diagnostic Products | — | — | — | — | |||||||||||
| Other | — | — | — | — | |||||||||||
| Total | $4.45B | $4.66B | $4.37B | $4.25B |
Perrigo brought in $4.25B from its two segments in fiscal 2025, the year ended December 31, 2025. That was down 2.8% from $4.37B in fiscal 2024. Csca was the largest at $2.59B (60.8%), ahead of Csci at $1.67B (39.2%).
Compared with fiscal 2024, Csci fell 0.7% to $1.67B and Csca fell 4.0% to $2.59B. From fiscal 2022 to 2025, combined revenue from these segments fell from $4.45B to $4.25B, a compound annual decline of 1.5%. Csca's share of the total fell from 65.7% to 60.8%.
United States was Perrigo’s largest region in fiscal 2025, bringing in $2.54B of $4.30B (59%).
| Geography | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | — | $2.92B | $2.65B | $2.54B | |||||||||||
| U.S | $2.87B | — | — | — | |||||||||||
| Unites States | — | — | — | — | |||||||||||
| Europe | $1.47B | $1.62B | $1.60B | $1.62B | |||||||||||
| Outside United States | — | — | — | — | |||||||||||
| All Other Countries | $107.30M | $116.30M | $119.50M | $96.70M | |||||||||||
| Ireland | $29.30M | $40.80M | $39.60M | $42.10M | |||||||||||
| Total | $4.48B | $4.70B | $4.41B | $4.30B |
Perrigo brought in $4.30B from its four regions in fiscal 2025, the year ended December 31, 2025. That was down 2.7% from $4.41B in fiscal 2024. United States was the largest at $2.54B (59.1%), ahead of Europe at $1.62B (37.6%) and All Other Countries at $96.70M (2.3%). The remaining region, Ireland, brought in $42.10M.
Compared with fiscal 2024, Europe grew fastest, up 0.7% to $1.62B, while All Other Countries fell the most, down 19.1% to $96.70M.
Perrigo stopped reporting U.S as a separate region after fiscal 2022, when it brought in $2.87B.
Perrigo (PRGO) reports its revenue by product and service, by segment and by geography. In fiscal 2025, Upper Respiratory was its largest product and service line, bringing in $817.70M (19.2% of the total), followed by Skin Care at $622.60M (14.6%).
Upper Respiratory was Perrigo's largest product and service line in fiscal 2025, bringing in $817.70M, or 19.2% of the $4.25B total across its 11 product and service lines.
Csca was Perrigo's largest segment in fiscal 2025, bringing in $2.59B, or 60.8% of the $4.25B total across its two segments.
United States was Perrigo's largest region in fiscal 2025, bringing in $2.54B, or 59.1% of the $4.30B total across its four regions.
Among Perrigo's product and service lines that make up at least 2% of revenue, Upper Respiratory grew fastest in fiscal 2025, up 4.5% from $782.40M to $817.70M.
Every figure comes from Perrigo's annual financial filings, as reported. Each line keeps the name Perrigo gives it, and years follow its fiscal calendar.
Perrigo's revenue by product and service goes back to fiscal 2014, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.